Combination pharmacological therapies for the management of benign prostatic hyperplasia.

摘要: Benign prostatic hyperplasia (BPH) is a highly prevalent condition of older men caused by unregulated growth the prostate gland. Clinical trials medical therapy for BPH have consistently demonstrated that combined with an α1-adrenergic receptor (AR) antagonist and 5α-reductase inhibitor superior to either agent alone. The addition anticholinergic treatment regimen could effectively improve symptoms in persistent storage lower urinary tract (LUTS) who not seen benefit α1-AR or inhibitor. Among antagonists, doxazosin, terazosin, tamsulosin, alfuzosin, although slight differences adverse event profiles, are equivalent effectiveness efficacy. No data form direct comparator exist suggest difference clinical efficacy finasteride dutasteride, two inhibitors currently available. Current American Urological Association guidelines do recommend phytotherapy dietary supplements any combination management BPH. current literature supports safety symptomatic and, select patients, use medication LUTS suggestive